McDonald's restaurants donate over $6K through fundraiser
HENDERSON, Ky. (WEHT) – According to officials, local McDonald's restaurants presented a donation of $6,424 to Ronald McDonald House Charities (RMHC) of the Ohio Valley on Friday as part of the annual Shamrock Shake fundraiser.
Officials say throughout the fundraiser, 25 cents from every Shamrock Shake and OREO Shamrock McFlurry sold at participating locations was donated to support RMHC's mission of keeping families close during difficult times.
Posey County couple married for over 50 years win Hadi Half-Pot raffle
A spokesperson says the check was presented by representatives from locally-owned McDonald's restaurants who participated in the initiative. Together, the organizations are supporting RMHC of the Ohio Valley and the services it provides to families with critically ill children.
14-day closures needed for roads north of the Lloyd
'Each shake sold represented more than just a sweet treat—it was a show of support for families facing some of their toughest moments,' said Katie Kenworthy, local McDonald's Owner/Operator and RMHC Board Member. 'We're grateful for our customers and crew members who made this donation possible.'
Officials say RMHC of the Ohio Valley offers a home-away-from-home for families while their children receive medical care, providing lodging, meals and emotional support—all at no cost to them.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Matthew 25 unveils mobile STD testing unit
HENDERSON, Ky (WEHT) – The non-profit organization Matthew 25 held a ribbon cutting to celebrate its campaign to help prevent, educate and treat people in the Tri-State with Sexual Transmitted Diseases. Last August, The Centers for Disease Control and Prevention granted $3,000,000 in funding to the organization. Matthew 25 used a large portion of that grant in partnership with Mission Mobile Medical to customize the treatment center. As for why this was needed, Chief Executive Officer, Courtney Woolfork, said, 'We have clinics in Owensboro, Henderson, and Bowling Green. But everything in between is really hard for people to get access to, because there isn't public transportation always.' The non-profit covers 25 counties in Kentucky and 12 in Indiana and officials say that they have seen STD trends increasing in those regions. Woolfork says that trends like these are why it's so beneficial to have a mobile treatment unit that can serve vulnerable areas. The mobile unit will also have PREP pills available to those who have had a Sexually Transmitted Illnesses. Matthew 25 urges those who have come in contact with an STD or STI to get this pill to lessen their chances of contracting HIV in the future. Over the next couple months, Woolfork and her team plan on traveling to 25 counties in the Tri-State. March 27 will kick off the road trip, as they will be in Owensboro, Kentucky for National HIV Testing Day. Although they are fighting an uphill battle the mission statement is clear, 'Meeting people where they are and however they are.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
17 hours ago
- Yahoo
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue originally appeared on TheStreet. Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. 💵💰💰💵 As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk () , while Eli Lilly () makes Zepbound and Mounjaro. One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's () and Domino's Pizza () . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 years Major restaurant chain quietly closes several locations Iconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. 'But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market,' said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients."Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $ Pizza, McDonald's rating surprise tied to persistent consumer issue first appeared on TheStreet on Jun 10, 2025 This story was originally reported by TheStreet on Jun 10, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected
GLP-1 investors haven't gained as much as expected from others' losses. Since the FDA approved Wegovy, also known as semaglutide, as an injectactable treatment to help people manage their weight, several exchange-traded funds tracking the performance of the company and its rivals in GLP-1 medications have largely failed to reflect the massive popularity of the drugs themselves. Still, the companies behind the funds seem to be staying the course, with faith that the drugs will appeal to increasingly wider audiences — offering healthcare investors an opportunity to get in before the market peaks. READ ALSO: WisdomTree Branches Out to Private Credit and Asset Managers Aren't Playing the Dual Share Class Waiting Game The main ETFs in the weight-loss drug segment are the Tema Cardiovascular and Metabolic ETF (HRTS), the Roundhill GLP-1 and Weight Loss ETF (OZEM) and Amplify Weight Loss Drug & Treatment ETF (THNR). Despite THNR hitting a 52-week high recently — roughly $22 a share, up from a low of $18.56 a share — both it and HRTS have fallen 11% over the past year. HRTS, the first to launch, has holdings in 30 to 40 companies. 'It's a strategy which has done well, but frankly, has been volatile,' Maurits Pot, the founder and CEO of Tema ETF Management, said. OZEM, the second-largest of the funds by assets, has outperformed the other two, gaining more than 5% in the same period. One reason for the underwhelming returns is that the funds' main holdings are primarily in a handful of pharmaceutical giants such as Ozempic manufacturer Novo Nordisk, whose stock has underperformed of late. Other major holdings for all three products include Eli Lilly & Co., Zealand Pharma and Roche Holding AG. The healthcare field as a whole is facing volatility, Pot noted, making it all the more important for investors to remain calm. 'This is a strategy which is differentiated by construction, differentiated by how people can approach it,' he said. All three funds also have relatively high expense ratios: OZEM and THNR's ratios sit at 0.59%, while HRTS has a whopping 0.75% fee: OZEM launched in May 2024 and has $37 million in AUM. HRTS launched in November 2023 and has $51.8 million in AUM. THNR launched in May 2024 and has $2.9 million in AUM. Ozempi-mania: Despite the challenges, there may be reason for optimism about the niche's future as competition in the weight-loss drug marketplace ramps up. Since 2021, new prescription and over-the-counter weight-loss drug medications have hit the market following FDA approval, under names like Zepbound, Olistat, and Contrave. Investors may also want to get in on the weight-loss drug market for its non-weight-loss effects: Recent trials have shown the drugs may help to protect against dementia.'There'll be short-term volatility,' Pot said. 'Our view is that won't last forever, and the need has never been greater.' This post first appeared on The Daily Upside. To receive exclusive news and analysis of the rapidly evolving ETF landscape, built for advisors and capital allocators, subscribe to our free ETF Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
